Rotterdam, The Netherlands | Genolier, Switzerland | June 2019
Swiss Medical Network advances the implementation of their artificial intelligence strategy by installing Quantib® ND Plus. Quantib’s state-of-the-art machine learning radiology software provides neurology tools for quantification and tracking of changes in the brain related to multiple sclerosis and different types of dementia such as Alzheimer's disease.
“We embraced the usage of Quantib® ND Plus because it offers the combination of quantified information for our dementia patients, as well as objective measurements of disease progression for our multiple sclerosis patients,” said Dr méd. Anne - Sophie Knoepfli - Wilson, neuroradiologist at Swiss Medical Network. “The software enables Swiss Medical Network to further improve the quality of care delivered to these specific patient groups.”
Rudolf Scholte, Founder of Quantib, commented: “We are delighted to add Swiss Medical to our network of highly valued relations. We see this as a big step forward to enhance our presence in Switzerland and the whole Alpine region.”
Swiss Congress of Radiology
This week the Scientific Committee of the Swiss Society of Radiology (SGR-SSR) organizes the Swiss Congress of Radiology at St. Gallen, Switzerland. Over 1200 attendees ranging from radiologists, nuclear medicine specialists and radiographers will participate in this covering topics including artificial intelligence and radiomics. Quantib will be present at the exhibition to showcase their radiology software as installed at Swiss Medical Network.
About Swiss Medical Network
Swiss Medical Network is among the leading Swiss private clinic groups. With 15 private health care facilities it provides superior care across Switzerland. Their specializations lay in 11 fields including radiology, neurosurgery and radiation oncology. Through their competence centers the healthcare organization provides specialized care and services by performing over 50 000 interventions every year.1
About Quantib
Quantib, market leader in artificial intelligence tools for radiology, strives for faster and more accurate diagnoses, supporting adequate and timely patient care. Using advanced machine learning and deep learning techniques, Quantib’s products can detect changes in tissue sooner than would be possible with the naked eye. Quantib has multiple products cleared by FDA and CE marked. These products are focused on the detection of changes in the brain related to diseases such as dementia and MS. The company is collaborating with, amongst others, Erasmus MC Rotterdam and UMC Utrecht, for the development of other AI applications.
For more information on Quantib and their products please visit www.quantib.com/solutions
Bibliography